Recce Pharmaceuticals Ltd

RCE

Recce Pharmaceuticals Ltd. is engaged in the research and development of pharmaceutical drugs that kill germs. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-01-15. The firm's anti-infective pipeline includes three broad-spectrum, synthetic polymer anti-infectives: RECCE 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE 435 as an orally administered therapy for bacterial infections; and RECCE 529 for viral infections. Through their multi-layered mechanisms of action, the Company's anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses. All RECCE compounds are water soluble at all pH levels in their liquid form.

Vanguard Australian Shares Index ETF

VAS

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

EBR Systems Inc.

EBR

EBR Systems, Inc. engages in the development of implantable systems for wireless tissue stimulation. The company is headquartered in Sunnyvale, California. The company went IPO on 2021-11-24. The firm is engaged in developing and commercializing Wireless Stimulation Endocardially (WiSE), an implantable, cardiac pacing device able to provide stimulation to endocardial (inside the heart) heart tissue for the correction of heart rhythm conditions without requiring the use of leads. WiSE offers leadless solutions for LV Pacing, including cardiac resynchronization therapy (CRT) and conduction system pacing (CSP). The firm also offers CRT devices through the CRM subsegment under the brand names, including Visionist X4 CRT-P, Valitude X4 (CRT-P), Momentum CRT-D, Resonate X4 CRT-D, and Vigilant X4 CRT-D, among others. The firm operates various subsidiaries, which include EBR Systems (AUST) Pty. Ltd. and EBR Systems (UK) Limited, which establish clinical trials in Australia and the United Kingdom, respectively.

iShares S&P 500 ETF

IVV

IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

Arafura Rare Earths Ltd

ARU

Arafura Rare Earths Ltd. engages in the exploration and development of mineral resource properties. The company is headquartered in Perth, Western Australia. The company went IPO on 2003-11-05. The firm produces rare earth products from the Nolans Project. The Nolans Project consists of a mine, process plant, including beneficiation, extraction and separation plants, and related infrastructure to be constructed and located at the Nolans site, approximately 135 kilometers north of Alice Springs in Australia's Northern Territory. Its rare earth products are Neodymium-Praseodymium (NdPr) oxide, and Mixed middle-heavy rare earths (SEG/HRE) oxide. NdPr oxide is the Company's flagship product, which is used by magnet and magnet alloy customers. The Company’s primary products from the Nolans project are rare earths, which are used in catalytic converters in automobiles, consumer electronics, energy efficiency lighting, optics, alloys, advanced ceramics and permanent magnets that enable e-mobility and renewable energy applications.